Newsletter
Language
Language:
 
News
Archival Issues
Volume 18, 2016
Volume 17, 2015
Volume 16, 2014
Volume 15, 2013
Volume 14, 2012
Volume 13, 2011
Volume 12, 2010
Volume 11, 2009
Volume 10, 2008
Volume 9, 2007
Volume 8, 2006
Volume 7, 2005
Volume 6, 2004
Volume 5, 2003
Volume 4, 2002
Volume 3, 2001
Volume 2, 2000
Volume 1, 1999
Search
 » 
Journal Abstract
 
New trends in the treatment of osteogenesis imperfecta type III – own experience
Elżbieta Jakubowska-Pietkiewicz , Danuta Chlebna-Sokół
Ortop Traumatol Rehabil 2008; 10(6):593-601
ICID: 877574
Article type: Original article
IC™ Value: 7.16
Abstract provided by Publisher
 
Introduction: Osteogenesis imperfecta (OI) is a genetic disorder caused by a mutation in the genes that encode the chains of type I collagen. Clinical manifestations include increased bone fragility and blue sclerae. OI type III is the most severe form with fractures occurring already in utero. Fracture immobilisation and orthopaedic surgery are the mainstay of treatment for patients with OI, and are combined with rehabilitation and bisphosphonate therapy.Patients and methods: The study involved 8 children with osteogenesis imperfecta type III, aged 1 month to 6 years. All of them were treated with cyclic intravenous infusions of pamidronate. Laboratory studies conducted before and after each 3-day cycle of pamidronate therapy included complete blood count, serum calcium, phosphorus, magnesium, osteocalcin, and calcium/creatinine index in morning urine and collagen type I cross-linked N-telopeptide (NTx). Infant total body densitometric scans were obtained in 5/8 patients.Results: Patients were treated for periods of 3-58 months. Fracture rates decreased with treatment in all patients compared to the prenatal period. Pamidronate also slowed down bone turnover, and particularly the resorption rate. The most common side effects during treatment included hypocalcaemia (7/8 patients) and fever (up to 39°C) after the first cycle of treatment.
Conclusion: Symptomatic bisphosphonate therapy in children with osteogenesis imperfecta ameliorated the clinical course (decreased bone pain and reduced incidence of fractures). Pamidronate therapy had a positive impact on functional parameters such as independence in everyday activities and better mobility. The treatment was safe.

ICID 877574
PMID 19153548 - click here to show this article in PubMed
 
FULL TEXT 960 KB


Related articles
  • in IndexCopernicus™
         pamidronian [1 related records]
         wrodzona łamliwość kości [0 related records]
         pamidronate [3 related records]
         bisphosphonates [10 related records]
         Osteogenesis Imperfecta [47 related records]

  • Related articlesin PubMed database
  • in PubMed database [ related records]


  •  

    Copyright © Ortopedia Traumatologia Rehabilitacja  2017
    Page created by Index Copernicus Ltd. All Rights reserved.